Compare HTLD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | CSTL |
|---|---|---|
| Founded | 1978 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.3M | 661.7M |
| IPO Year | N/A | 2019 |
| Metric | HTLD | CSTL |
|---|---|---|
| Price | $8.02 | $39.13 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $8.75 | ★ $38.67 |
| AVG Volume (30 Days) | 517.0K | ★ 573.2K |
| Earning Date | 10-31-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $868,930,000.00 | $343,530,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $7.00 | $14.59 |
| 52 Week High | $12.78 | $40.61 |
| Indicator | HTLD | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 58.46 | 76.91 |
| Support Level | $7.00 | $33.03 |
| Resistance Level | $8.00 | $40.61 |
| Average True Range (ATR) | 0.21 | 1.49 |
| MACD | 0.09 | 0.21 |
| Stochastic Oscillator | 90.85 | 78.50 |
Heartland Express Inc is engaged in providing truckload services across the United States, Mexico, and Canada. These truckload services are asset-based transportation services in the dry van truckload market. The company offers truckload temperature-controlled transportation services, and Mexico logistics services. A majority of its customers represent the consumer goods, appliances, food products, and automotive industries.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.